- |||||||||| Avastin (bevacizumab) / Roche
Journal: Clinical Efficacy of Bevacizumab Combined with Temozolomide in Treating Gliomas. (Pubmed Central) - May 17, 2024
BEV plus TMZ is remarkable in the treatment of patients with recurrent malignant gliomas. The combination treatment improves the DCR and PFS of patients and their quality of life, and does not increase adverse reactions, making it a promising approach that deserves widespread promotion and clinical application.
- |||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Retrospective data, Journal, Monotherapy, Metastases: Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study. (Pubmed Central) - May 17, 2024
Previous therapy with fruquintinib or regorafenib was allowed but not mandatory...Multivariate Cox regression analysis demonstrated that undergoing therapy after TAS-102 either with or without BEV was an independent risk factor for OS [hazard ratio (HR) =0.25; 95% confidence interval (CI): 0.09-0.71, P<0.01], and previous treatment with cetuximab was an independent protective factor for PFS (HR =0.17; 95% CI: 0.03-0.91, P=0.04)...There was a trend in favor of the combination of BEV plus TAS-102 regarding OS and DCR, without reaching statistical significance, and it means that there was no clear advantage of one over the other in terms of efficacy. Further prospective studies are still necessary to draw a definite conclusion.
- |||||||||| Avastin (bevacizumab) / Roche, Jemperli (dostarlimab-gxly) / GSK, Zejula (niraparib) / GSK, J&J
P2 data, Clinical Trial,Phase II, Journal, Combination therapy, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. (Pubmed Central) - May 16, 2024
P1b/2
Results demonstrated modest activity of niraparib, dostarlimab, and bevacizumab in participants with PROC, many of whom had prognostic factors for poor treatment response. Most participants with response were bevacizumab-na
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib. (Pubmed Central) - May 16, 2024
High-risk varices were independently associated with Child-Pugh B score (odds ratio [OR]: 2.12; 95% CI: 1.08-4.17, p = 0.03), nPVT (OR: 2.54; 95% CI: 1.40-4.61, p = 0.002), and platelets <150,000/?L (OR: 2.47; 95% CI: 1.35-4.50, p = 0.003). In hepatocellular carcinoma patients treated with lenvatinib, the risk of EGV bleeding was mostly low but significant only in patients with high-risk EGV at baseline.
- |||||||||| Retrospective data, Journal, Metastases: Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis. (Pubmed Central) - May 16, 2024
Phase 3 randomized controlled trials (RCTs) testing TKIs, including sorafenib and lenvatinib, or ICIs reporting overall survival (OS) and progression-free survival (PFS) were included...Atezolizumab plus bevacizumab showed the best net health benefit for OS, compared to durvalumab plus tremelimumab...Atezolizumab plus bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to atezolizumab plus bevacizumab, lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
- |||||||||| Journal, Metastases: Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. (Pubmed Central) - May 15, 2024
A cautious approach to systemic therapy is recommended for patients with Child-Pugh class B advanced HCC. Further guidance on choosing between options is included within the guideline.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Review, Journal, Combination therapy, Monotherapy, Metastases: Advances in monotherapy and combination therapy of S-1 for patients with advanced non-small cell lung cancer: a narrative review. (Pubmed Central) - May 13, 2024
As for the combination of S-1 and immunotherapy, preliminary results of a phase II retrospective clinical trial demonstrated that the ORR was significantly better with S-1 sequential after immune checkpoint inhibitors (ICIs) than with S-1 alone. The findings indicate promising effectiveness and minimal toxicity with S-1 monotherapy and S-1 containing combined therapy in patients with advanced NSCLC to provide a potential treatment option for advanced NSCLC.
- |||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Mitochondria-Derived Vesicles, Sterile Inflammation, and Pyroptosis in Liver Cancer: Partners in Crime or Innocent Bystanders? (Pubmed Central) - May 11, 2024
The lack of biomarkers that may allow prediction of treatment response and, therefore, patient selection, is a major unmet need. Herein, we overview the molecular mechanisms linking mitochondrial dysfunction, inflammation, and pyroptosis, and discuss how immunotherapy targets, at least partly, these routes.
- |||||||||| Avastin (bevacizumab) / Roche
Review, Journal: Chordoma Genetic Aberrations and Targeted Therapies Panorama: A Systematic Literature Review. (Pubmed Central) - May 11, 2024
PD-1 inhibitors were the most frequently utilized, appearing in 50% of the trials, followed by PD-L1 inhibitors (36.4%), CTLA-4 inhibitors (22.7%), and mTOR inhibitors (13.6%). This systematic review provides an extensive overview of the state of targeted therapy for chordomas, highlighting their potential to stabilize the illness and enhance clinical outcomes.
- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal: The Impact of Sequential Therapies after First-Line Systemic Therapies in Unresectable Hepatocellular Carcinoma. (Pubmed Central) - May 11, 2024
Pre-treatment ALBI grade had a significant impact on the decision to accept sequential therapy in patients with progressed HCC. The patients who were able to undergo sequential therapy had a better survival outcome compared to those who received only one agent, and the pre-treatment ALBI level might be regarded as a cornerstone tool to assess survival outcomes in patients undergoing treatment for HCC.
- |||||||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Aflibercept to treat retinopathy of prematurity: need for more research. (Pubmed Central) - May 11, 2024
We summarize the clinical trial results and provide a side-by-side comparisons of the three drugs. Despite FDA approval of the use of aflibercept to treat ROP, there is a need for more research as the body of knowledge regarding this agent to treat ROP is limited.
- |||||||||| Avastin (bevacizumab) / Roche
Journal: Arginine methylation of caspase-8 controls life/death decisions in extrinsic apoptotic networks. (Pubmed Central) - May 11, 2024
Furthermore, two potential methylation sites of PRMT5 on procaspase-8, R233 and R435, were identified in silico...Finally, the pharmacological inhibition of PRMT5 resulted in the inhibitory effects on caspase activity and apoptotic cell death. Taken together, we have unraveled the additional control checkpoint in procaspase-8 activation and the arginine methylation network in the extrinsic apoptosis pathway.
- |||||||||| Avastin (bevacizumab) / Roche
Review, Journal: Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options. (Pubmed Central) - May 10, 2024
We present a detailed analysis of the most extensively investigated resistance mechanisms, including drug inactivation, drug target alterations, enhanced drug efflux pumps, increased DNA damage repair capacity, and reduced drug absorption/accumulation. The in-depth understanding of the molecular mechanisms associated with drug resistance is crucial to unveil new biomarkers capable of predicting and monitoring the kinetics during disease progression and discovering new therapeutic targets.
- |||||||||| Review, Journal, Metastases: HER2-Positive Metastatic Colorectal Cancer. (Pubmed Central) - May 9, 2024
Trastuzumab plus lapatinib, trastuzumab plus pertuzumab, and trastuzumab deruxtecan (T-DXd) also have evidence of efficacy in this setting...These include the optimal sequence of anti-HER2 therapies with chemotherapy and anti-EGFR therapies, the optimal combination partners for anti-HER2 therapies, and the incorporation of predictive biomarkers to guide use of anti-HER2 therapies. Results of ongoing studies may thus alter the treatment paradigm above in the coming years.
- |||||||||| Avastin (bevacizumab) / Roche
SBRT in colorectal cancer patients with 1-10 metastases: a multicenter pilot study (NCT05375708) (Lomond Auditorium) - May 8, 2024 - Abstract #ESTRO2024ESRTO_15;
P2
The initial treatment effect of SBRT in combination with systemic therapy seems promising in patients with mCRC. However, because of highly effective systemic therapy, 38% of lesions vanished during systemic treatment resulting in no patient with six or more radiated lesions.
- |||||||||| Avastin (bevacizumab) / Roche
Journal: Direct antitumor activity of bevacizumab: an overlooked mechanism? (Pubmed Central) - May 8, 2024
Patients who are treated with Atezo/Bev and meet the inclusion criteria for the phase 3 IMbrave150 trial, as well as those who do not meet the inclusion criteria but have good liver function, have a good prognosis for survival. No abstract available
- |||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal: Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma. (Pubmed Central) - May 6, 2024
A protocol defined by aggressive pre-transplant liver-directed treatment and transplant for patients with undetectable disease or treatment-induced liver failure may help prevent recurrence of colorectal metastasis. In light of recent data demonstrating a lack of efficacy of 5-FU based chemotherapy, Atezo+Bev is a promising treatment option for patients with low-grade unresectable AA; further study is warranted.
- |||||||||| Avastin (bevacizumab) / Roche
Clinical data, Journal: Clinical Outcomes of Topical Bevacizumab for the Treatment of Corneal Neovascularization. (Pubmed Central) - May 6, 2024
As the outcome varies depending on the severity and chronicity of the condition, the attending ophthalmologist should treat each case differently. Although topical bevacizumab is more effective in mild and moderate cases, the indications for its use in chronic cases remain debatable as the results are unfavorable in such cases.
- |||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma. (Pubmed Central) - May 5, 2024
FFA aided in identifying occult neovascularization and prompted further treatment. Patients exhibiting elevated serum sodium levels derive the greatest benefit from immunotherapy, suggesting that baseline serum concentration could serve as a valuable and cost-effective predictive biomarker for immunotherapy across entities.
- |||||||||| Journal, Metastases: Sequencing considerations in the third-line treatment of metastatic colorectal cancer. (Pubmed Central) - May 3, 2024
Patients exhibiting elevated serum sodium levels derive the greatest benefit from immunotherapy, suggesting that baseline serum concentration could serve as a valuable and cost-effective predictive biomarker for immunotherapy across entities. Four treatments-regorafenib, trifluridine/tipiracil alone or with bevacizumab, and fruquintinib-are FDA-approved and recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
- |||||||||| rinatabart sesutecan (PRO1184) / ProfoundBio
Enrollment change, Trial completion date, Trial primary completion date, Metastases: PRO1184-001: PRO1184 for Advanced Solid Tumors (clinicaltrials.gov) - May 3, 2024
P1/2, N=374, Recruiting,
Four treatments-regorafenib, trifluridine/tipiracil alone or with bevacizumab, and fruquintinib-are FDA-approved and recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines N=134 --> 374 | Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: Jan 2025 --> Oct 2025
- |||||||||| Avastin (bevacizumab) / Roche
Review, Journal: Neuroimaging Features of Cytokine-related Diseases. (Pubmed Central) - May 2, 2024
N=134 --> 374 | Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: Jan 2025 --> Oct 2025 Several imaging manifestations have been well recognized owing to the development of cytokine therapies such as those with bevacizumab (antibody against vascular endothelial growth factor) and chimeric antigen receptor (CAR) T cells and the establishment of new disease concepts such as interferonopathy and cytokine release syndrome...The authors outline the neuroimaging features of cytokine-related diseases, focusing on cytokine storms, neuroinflammatory and neurodegenerative diseases, cytokine-related tumors, and cytokine-related therapies, and describe an approach to diagnosing cytokine-related disease processes and their differentials.
- |||||||||| Avastin (bevacizumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact (Pubmed Central) - May 2, 2024
Platinum doublets received 70.5% utilization for squamous NSCLC with PD-L1 expression <1% in first-line, whereas nonsquamous NSCLC was treated with platinum doublets (35.2%) or bevacizumab with platinum doublets (35.3%)...Driver-mutated NSCLC was most frequently treated with targeted therapy or platinum-based combinations. NSCLC treatment in China varies by histology, PD-L1 status
|
